Michela Luciano, PhD,  Science Writer—

Researchers in the U.S. have found that exposure to low oxygen levels — known as hypoxia — early in life can cause pulmonary hypertension (PH) by permanently altering lung blood vessel development. The team used a new mouse model they designed to better reflect a severe form of PH…

Cereno Scientific is seeking a green light from the U.S. Food and Drug Administration (FDA) to launch a global clinical trial testing its oral therapy CS1 — a repurposed drug now used for treating seizures — in people with pulmonary arterial hypertension (PAH). In PAH, the company hopes the…

The first clinical site is now active for a global Phase 3 study that will evaluate Gossamer Bio’s therapy candidate seralutinib in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Dubbed SERANATA, the study aims to enroll about 480 people with PH-ILD, ages 18 to 80. No…

An eight-week exercise program using kettlebells — a weight tool consisting of a heavy cast-iron ball and handle — led to gains in physical performance, breathing efficiency, and muscle strength in people with pulmonary arterial hypertension (PAH), according to a new study from Turkey. Kettlebell training also improved quality…

People with portopulmonary hypertension (PoPH), a form of pulmonary arterial hypertension (PAH) usually associated with liver disease, show lower five-year survival rates than people with other types of PAH. Common markers that help predict outcomes in other PAH forms failed to identify high-risk patients in this group, however. But…

The first participant has been dosed in a Phase 1 trial testing F230, an investigational oral therapy for pulmonary arterial hypertension (PAH). This clinical study (NCT06899815) seeks to enroll about 116 healthy individuals in China, ages 18 to 45. Around 68 participants will be randomly assigned to receive a…

The U.S. Food and Drug Administration (FDA) has granted breakthrough device status to the Gradient Denervation System, an ultrasound-based catheter for treating pulmonary hypertension (PH). A breakthrough designation is given to medical devices that may offer significant advantages over existing treatments for irreversibly debilitating or life-threatening conditions. It’s intended…